

---

## Acetylcholine Receptor Ab ELISA Kit

---

Cat.No: DEIABL27

Lot. No. (See product label)

### Size

96T

### Intended use

The CD Acetylcholine Receptor Autoantibody (AChRab) ELISA kit is intended for use by professional persons only, for the quantitative determination of AChRab in human serum. Autoantibodies to the acetylcholine receptor (AChR) are responsible for failure of the neuromuscular junction in myasthenia gravis. Measurement of these antibodies can be of considerable value in disease diagnosis and management.

### Principle Of The Test

CD's AChRab ELISA depends on the ability of AChRab in human serum to bind to similar sites on the AChR as various monoclonal antibodies such as MAb1 (coated on ELISA plate wells) and/or MAb2 and/or MAb3 (which are labelled with Biotin). In the absence of AChRab a complex is formed between MAb1 coated on the plate wells, the AChR and MAb2- and MAb3-Biotin. MAb2- and MAb3-Biotin bound are then detected by addition of Streptavidin Peroxidase (SA-POD), which binds specifically to Biotin. Excess, unbound SA-POD is then washed away and addition of the peroxidase substrate 3,3',5,5'-tetramethylbenzidine (TMB) results information of a blue colour. This reaction is stopped by addition of stop solution causing the well contents to turn yellow. The absorbance of the yellow reaction mixture at 450 nm is then read using an ELISA plate reader. In the presence of AChRab the formation of the MAb1-AChR-MAb2-/MAb3-Biotin complex is inhibited, resulting in less SA-POD being bound and are duction in final absorbance at 450nm. The higher the concentration of AChRab in the test serum, the greater the inhibition of MAb-Biotin binding. When using the kit calibrators, the measuring interval is 0.45-20 nmol/L toxin bound.

### Reagents And Materials Provided

**A. AChR MAb1 Coated Wells**, 12 breakapart strips of 8 wells (96 intotal) in a frame and sealed in a foil bag. Allow foilbag to stand at room temperature (20-25°C) for 30 minutes before opening.

Ensure wells are firmly fitted in the frame provided. After opening return any unused wells to the original foil bag and seal with adhesive tape. Then place foil bag in the self-seal plastic bag with desiccant provided, and store at 2-8°C for up to kit expiry date.

**B. Foetal Type AChR**, 3 vials, Lyophilised

Reconstitute each vial with 0.7 mL reconstitution buffer for AChR (D). Mix gently, and leave to stand at room temperature (20-25°C) for 5 minutes before use. Pool the vials when more than one vial is required, and then use immediately to reconstitute adult type AChR.

**C. Adult Type AChR**, 3 vials, Lyophilised

**B+C:**

Reconstitute each vial of C with 0.5 mL of reconstituted foetal type AChR (B) to give a mixture of foetal and adult AChR (B+C).

Mix gently, and leave to stand at room temperature (20-25°C) for 5 minutes before use. Pool the vials when more than one vial is required. Use up to 6 hours after reconstitution if stored at 2-8°C.\*

D. **Reconstitution Buffer for AChR**, 5 mL, Ready for use

E. **AChR MAb - Biotin (MAb2+MAb3)**, 3 vials, Lyophilised

Reconstitute each vial with the volume of reconstitution buffer for MAb-Biotin (F) shown on the vial label. Mix gently, and leave to stand at room temperature (20-25°C) for 5 minutes before use. Pool the vials when more than one vial is required. Store at 2-8°C for up to kit expiry date after reconstitution.

F. **Reconstitution Buffer for MAb - Biotin**, 15 mL, Ready for use

G. **Streptavidin Peroxidase (SA - POD)**, 0.7 mL, Concentrated

Dilute 1 in 20 with diluent for SA-POD (H). For example, 0.5 mL (G) + 9.5 mL (H). Store at 2-8°C for up to kit expiry date after dilution.

H. **Diluent for SA - POD**, 15 mL, Ready for use

J. **Peroxidase Substrate (TMB)**, 15 mL, Ready for use

K. **Stop Solution**, 10 mL, Ready for use

L. **Concentrated Wash Solution**, 100 mL, Concentrated

Dilute 10 X with pure water before use. For example, 100 mL (L) + 900 mL pure water. Use up to kit expiry date after dilution.

M1-4. **Calibrators**, 0.5, 1.0, 6.5 and 20 nmol/L toxin bound, 4 x 0.7 mL, Ready for use

N. **Negative Control**, 3 mL, Ready for use

P1-2. **Positive Controls I & II** (see label for concentration range), 2 x 0.7 mL, Ready for use

\* The absorbance at 450 nm will be 10-15% lower when reconstituted receptors have been stored for 6 hours at 2-8°C.

## Materials Required But Not Supplied

1. Pipettes capable of dispensing 25 µL, 50 µL and 100 µL.
2. Eppendorf type repeating pipette.
3. Means of measuring various volumes to reconstitute, or dilute reagents supplied.
4. Eppendorf tubes.
5. Pure water.
6. ELISA Plate reader suitable for 96 well formats and, capable of measuring at 450nm.
7. ELISA Plate shaker, capable of 500 shakes/min (not, an orbital shaker).
8. ELISA Plate cover.

## Specimen Collection And Preparation

Sera to be analysed should be assayed soon after separation or stored, preferably in aliquots, at or below -20°C. 100 µL is sufficient for one assay (duplicate 50 µL determinations). Repeated freeze thawing or increases in storage temperature must be avoided. Do not use lipaemic or haemolysed serum samples. Studies in which EDTA, citrate and heparin plasma samples were

spiked with AChRAb positive sera showed minor changes in signal compared with spiked serum from the same donor. In particular OD 450 values with spiked EDTA, citrate and heparin plasmas were 83% - 122% of spiked serum (20 samples with serum concentrations ranging from 0.28 nmol/L - 18 nmol/L) or 69% - 165% in terms of nmol/L.

When required, bring test sera to room temperature and mix gently to ensure homogeneity. Centrifuge serum prior to assay (preferably for 5 min at 10-15,000 g in a microfuge) to remove particulate matter. Please do not omit this centrifugation step if sera are cloudy or contain particulates.

## Assay Procedure

Allow all reagents to stand at room temperature (20-25°C) for at least 30 minutes prior to use. A repeating Eppendorf type pipette is recommended for steps 2, 5, 7, 9 and 10.


1. Pipette **100 µL** of samples [calibrators (M 1-4 - optional), positive controls (P 1-2), and negative control (N) and test sera] into individual 1.5 mL Eppendorf tubes, labelled accordingly.
2. Pipette **25 µL** of foetal and adult type AChR mixture (B+C) into each Eppendorf tube (from step 1) and seal the tubes. Make sure that all liquid is in the bottom of each tube (if in doubt centrifuge the tubes in a microfuge for 10 seconds at 10-15,000g). Vortex gently and incubate overnight (16-20 hours) at 2-8°C.
3. Gently mix each tube of sample-AChR mixture from step 2 using a vortex mixer. Pipette duplicate **50 µL** of each sample-AChR mixture into the AChR MAb1 coated wells (A) leaving 2 wells empty for blanks. Cover the frame and incubate at room temperature on an ELISA plate shaker (500 shakes per min) for 1 hour.
4. Aspirate the wells by use of a plate washing machine or discard by briskly inverting the frame of wells over a suitable receptacle. Wash the wells three times with diluted wash solution (L). For manual washing tap the inverted wells gently on a clean dry absorbent surface to remove excess wash.
5. Pipette **50 µL** of reconstituted AChR MAb-Biotin (E) into each well (except blanks). Cover the frame and incubate at room temperature on an ELISA plate shaker (500 shakes per min) for 1 hour.
6. Repeat wash step 4.
7. Pipette **100 µL** of diluted SA-POD (G) into each well (except blanks). Cover the frame and incubate at room temperature on an ELISA plate shaker (500 shakes per min) for 30 minutes.
8. Repeat wash step 4. For manual washing, wash once more with pure water to remove any foam. Tap the inverted wells gently on a clean, dry, absorbent surface to remove excess wash.
9. Pipette **100 µL** of TMB (J) into each well (including blanks). Cover the frame and incubate in the dark at room temperature for 30 minutes without shaking.
10. Pipette **50 µL** stop solution (K) to each well (including blanks), cover the frame and shake for approximately 5 seconds on a plate shaker. Ensure substrate incubations are the same for each well.
11. Within 30 minutes, read the absorbance of each well at 450nm using an ELISA plate reader, blanked against the wells containing **100 µL** of TMB (J) and **50 µL** stop solution (K) only.

## Interpretation Of Results

A calibration curve can be established by plotting calibrator concentration (including a value of 0.2 nmol/L for the negative control) on the x-axis (linear scale) against the absorbance of the calibrators on the y-axis (linear scale). The AChRAb concentrations in patients' sera can then be read off the calibration curve. The data in these instructions are based on a 4 parameter curve fit. Samples with high AChRAb concentrations can be diluted in negative control (N). For example 10 µL of sample plus 90 µL of negative control (N) to give a 10x dilution. Other dilutions (e.g. 100x) can be prepared from a 10x dilution or otherwise as appropriate. Some sera will not dilute in a linear way and we suggest that the dilution giving a value closest to 50% inhibition is used for calculation of AChRAb concentration.

## Typical Standard Curve

Sample	Abs. 450 nm	Conc. nmol/L
Negative Control N	1.970	0.2 <sup>2</sup>
M1	1.616	0.5
M2	1.329	1.0
M3	0.524	6.5
M4	0.144	20
Positive Control P1	0.469	7.5
Positive Control P2	1.124	1.6



Results can also be expressed as inhibition (%I) of AChR binding calculated using the formula:

$$100 \times [1 - (\text{test samples absorbance at 450}) / (\text{negative control absorbance at 450})]$$

This % inhibition value can then be converted to nmol/L toxin bound using the formula;

$$0.2 \times 2^{(0.067 \times \% \text{ inhibition of test sample})}$$

This formula has been established empirically using a comparison of AChRAb measurements by the CD ELISA and RIA methods. Close agreement between nmol/L values obtained in the AChRAb ELISA using the calibration curve and using this formula should not be expected in the case of all individual sera.

### TYPICAL RESULTS USING % INHIBITION

Sample	Abs. 450nm	% Inhibition	Calculated nmol/L
Negative Control N	1.97	0	0.2
Positive Control P1	0.46	76.2	6.9
Positive Control P2	1.12	42.9	1.5

**ASSAY CUT OFF:**

**Negative** < 0.45 nmol/L

**Positive** ≥ 0.45 nmol/L

**Precision**

**Inter Assay Precision (n = 20)**

Sample	% Inhibition	CV (%)	nmol/L	CV (%)
1	76.4	3.3	7.7	8.7
2	52.4	6.7	2.0	11.1
3	27.3	9.4	0.62	9.4

**Intra Assay Precision (n = 24)**

Sample	% Inhibition	CV (%)	nmol/L	CV (%)
4	90.8	0.6	13.5	2.5
5	45.9	2.4	1.7	5.2
6	25.9	7.1	0.67	8.5

## Detection Limit

The negative control was assayed 20 times and the mean and standard deviation calculated. The lower detection limit at 2 standard deviations was 0.25 nmol/L.

## Sensitivity

Sera from 83 patients diagnosed with myasthenia gravis were assayed in the AChRAB ELISA. 76 (92%) were identified as being positive for AChRAB.

### Clinical Accuracy

Analysis of 107 sera from patients with autoimmune diseases other than myasthenia gravis indicated no interference from autoantibodies to thyroglobulin (n=10), thyroid peroxidase (n=11), dsDNA (n=9), TSH receptor (n=40), glutamic acid decarboxylase (n=10), 21-hydroxylase (n=10), or from rheumatoid factor (n=27). Two other samples gave values of 28% (0.74 nmol/L) and 44% (1.5 nmol/L) inhibition and were from a patient with Graves' disease (TRAb positive) and a patient with Systemic Lupus Erythematosus (dsDNA Ab positive) respectively. These samples were assayed in the CD AChRAB RIA kit and were positive (values of 1.3 and 1.5 nmol/L respectively). In addition two samples from patients with rheumatoid arthritis (rheumatoid factor positive) were positive in the CD AChRAB ELISA and gave values of 24% (0.77 nmol/L) and 19% (0.61 nmol/L) inhibition. The first of these samples was also positive in the CD AChRAB RIA (5.3 nmol/L).

## Specificity

Sera from 402 individual healthy blood donors were assayed in the AChRAB ELISA. 401 (99.8%) were identified as being negative for AChRAB. One sample was positive and gave a value of 20% inhibition (0.54 nmol/L from the calibration curve, 0.52 nmol/L calculated).

## Interferences

No interference was observed when samples were spiked with the following materials; haemoglobin at 500 mg/dL, bilirubin at 20 mg/dL or Intralipid up to 3000 mg/dL.

The data quoted in these instructions should be used for guidance only. It is recommended that each laboratory include its own panel of control samples in the assay. Each laboratory should establish its own normal and pathological reference ranges for AChRAB levels.

## Precautions

This kit is intended for in vitro use by professional persons only. Follow the instructions carefully. Observe expiry dates stated on the labels and the specified shelf life for coated wells, diluted or reconstituted reagents. Refer to Safety Data Sheet for more detailed safety information. With all kit components, avoid ingestion, inhalation, injection or contact with skin, eyes or clothing. Wear protective clothing. Material of human origin used in the preparation of the kit has been tested and found non-reactive for HIV1 and 2 and HCV antibodies and HBsAg but should, none-the-less, be handled as potentially infectious. Wash hands thoroughly if contamination has occurred and before leaving the laboratory. Sterilise all potentially contaminated waste, including test specimens before disposal. Material of animal origin used in the preparation of the kit has been obtained from animals certified as healthy but these materials should be handled as potentially infectious. Some components contain small quantities of sodium azide as preservative. Avoid formation of heavy metal azides in the drainage system by flushing any kit components away with copious amounts of water.